GR1003861B - Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa. - Google Patents

Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.

Info

Publication number
GR1003861B
GR1003861B GR20000100470A GR2000100470A GR1003861B GR 1003861 B GR1003861 B GR 1003861B GR 20000100470 A GR20000100470 A GR 20000100470A GR 2000100470 A GR2000100470 A GR 2000100470A GR 1003861 B GR1003861 B GR 1003861B
Authority
GR
Greece
Prior art keywords
present
anxiety
neurosteroids
formula
compounds
Prior art date
Application number
GR20000100470A
Other languages
English (en)
Inventor
Original Assignee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by filed Critical
Priority to GR20000100470A priority Critical patent/GR1003861B/el
Priority to AU2002217353A priority patent/AU2002217353A1/en
Priority to PCT/GR2001/000048 priority patent/WO2002053577A2/en
Priority to US10/250,334 priority patent/US7064116B2/en
Publication of GR1003861B publication Critical patent/GR1003861B/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0007—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
    • C07J5/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0027—Azides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

παρούσα εφεύρεση αναφέρεται σε νέα ανάλογα στεροειδών τα οποία επιδρούν στον ιοντοφόρο σύμπλεγμα υποδοχέας γ-αμινοβουτυρικού οξέος-κανάλι χλωρίου καθώς επίσης και μεθόδους για τη σύνθεση αυτών και εφαρμογή τους σαν αναισθητικά, για την αντιμετώπιση του stress, άγχους, αυπνίας, επιληψίας , PMS, PDN και για τη βελτίωση ή πρόληψη επεισοδίων άγχους, μυικής τάσης και κατάθλιψης οι οποίες είναι καταστάσεις που απαντώνται σε ασθενείς που υποφέρουν απο διαταραχές του κεντρικού νευρικού συστήματος. Η παρούσα εφεύρεση περιλαμβάνει ενώσεις του τύπου (Ι) όπου τα R1,R2,R3,R4,R5 προσδιορίζονται στην Περιγραφή της εφεύρεσης Επίσης μέρος της εφεύρεσης αποτελούν και φαρμακοτεχνικές μορφές που περιλαμβάνουν μία ή και περισσότερες απο τις ενώσεις του τύπου (Ι). ΰ
GR20000100470A 2000-12-29 2000-12-29 Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa. GR1003861B (el)

Priority Applications (4)

Application Number Priority Date Filing Date Title
GR20000100470A GR1003861B (el) 2000-12-29 2000-12-29 Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
AU2002217353A AU2002217353A1 (en) 2000-12-29 2001-12-21 Gabaa modulating neurosteroids
PCT/GR2001/000048 WO2002053577A2 (en) 2000-12-29 2001-12-21 Gabaa modulating neurosteroids
US10/250,334 US7064116B2 (en) 2000-12-29 2001-12-21 GABAA modulating neurosteroids

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GR20000100470A GR1003861B (el) 2000-12-29 2000-12-29 Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.

Publications (1)

Publication Number Publication Date
GR1003861B true GR1003861B (el) 2002-04-11

Family

ID=10944475

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20000100470A GR1003861B (el) 2000-12-29 2000-12-29 Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.

Country Status (4)

Country Link
US (1) US7064116B2 (el)
AU (1) AU2002217353A1 (el)
GR (1) GR1003861B (el)
WO (1) WO2002053577A2 (el)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2275096A3 (en) 2005-08-26 2011-07-13 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2008030651A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
CA2955684A1 (en) * 2008-02-26 2009-09-03 Emory University Steroid analogues for neuroprotection
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CZ2009521A3 (cs) * 2009-08-04 2010-09-15 Ústav organické chemie a biochemie, Akademie ved CR, v.v.i. 3alfa-Hydroxy-21ksí,22-oxido-21-homo-5alfa-pregnan-20-on, zpusob jeho výroby a jeho použití
AU2011284606A1 (en) * 2010-07-30 2013-03-14 Pharmacellion Ltd Compounds and methods for treating neoplasia
US9388210B2 (en) 2011-02-25 2016-07-12 Washington University Neuroactive 17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
HUE062616T2 (hu) 2011-09-08 2023-11-28 Sage Therapeutics Inc Neuroaktív szteroidok, készítmények és alkalmazásaik
US10478505B2 (en) 2011-09-23 2019-11-19 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
EP4717314A2 (en) 2011-10-14 2026-04-01 Sage Therapeutics, LLC 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
SG10201606063RA (en) 2012-01-23 2016-09-29 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
RS62761B1 (sr) * 2012-08-21 2022-01-31 Sage Therapeutics Inc Alopregnanolon za lečenje refraktornog epileptičkog statusa
US20150313915A1 (en) 2012-11-30 2015-11-05 The Regents Of The University Of California Anticonvulsant activity of steroids
DK2935307T3 (en) * 2012-12-18 2018-07-30 Univ Washington NEUROACTIVE 19-ALKOXY-17-SUBSTITUTED STEROIDS USED IN METHODS OF TREATMENT
US9512170B2 (en) 2013-03-01 2016-12-06 Washington University Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors
US9365502B2 (en) 2013-03-11 2016-06-14 Washington University Neuroactive substituted cyclopenta[b]phenanthrenes as modulators for GABA type-A receptors
FI3932932T3 (fi) * 2013-03-13 2025-10-15 Sage Therapeutics Inc Neuroaktiivisia steroideja ja niiden käyttömenetelmiä
US9562026B2 (en) 2013-03-14 2017-02-07 Washington University Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors
US9725481B2 (en) 2013-04-17 2017-08-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
CN117304245A (zh) 2013-04-17 2023-12-29 萨奇治疗股份有限公司 刺激神经活性的19-去甲类固醇及其使用方法
CA2918735C (en) 2013-07-19 2023-08-01 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
CN105579043B (zh) 2013-08-23 2021-09-14 萨奇治疗股份有限公司 神经活性类固醇、组合物和其用途
JP6628745B2 (ja) 2014-06-18 2020-01-15 セージ セラピューティクス， インコーポレイテッド オキシステロールおよびその使用方法
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
MY190408A (en) 2014-10-16 2022-04-21 Sage Therapeutics Inc Compositions and methods for treating cns disorders
US20170233433A1 (en) 2014-10-16 2017-08-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
LT3250210T (lt) 2015-01-26 2021-04-12 Sage Therapeutics, Inc. Kompozicijos ir būdai, skirti gydyti cns sutrikimus
DK3258939T3 (da) 2015-02-20 2022-12-12 Sage Therapeutics Inc Neuroaktive steroider, sammensætninger og anvendelser heraf
DK3812392T3 (da) 2015-07-06 2025-07-21 Sage Therapeutics Inc Oxysteroler og fremgangsmåder til anvendelse deraf
PT3319611T (pt) 2015-07-06 2021-04-22 Sage Therapeutics Inc Oxisteróis e métodos de utilização dos mesmos
WO2017007832A1 (en) 2015-07-06 2017-01-12 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
PH12018501923B1 (en) 2016-03-08 2024-06-28 Sage Therapeutics Inc Neuroactive steroids, compositions, and uses thereof
ES2921010T3 (es) 2016-04-01 2022-08-16 Sage Therapeutics Inc Oxisteroles y procedimientos de uso de los mismos
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2018009867A1 (en) 2016-07-07 2018-01-11 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
CA3030420C (en) 2016-07-11 2025-11-18 Sage Therapeutics, Inc. C7, C12 AND C16 SUBSTITUTED NEUROACTIVE STEROIDS AND ASSOCIATED METHODS OF USE
WO2018013613A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
MA46351A (fr) 2016-09-30 2021-06-02 Sage Therapeutics Inc Oxystérols substitués en c7 et procédés en tant que modulateurs nmda
DK3529257T3 (da) 2016-10-18 2023-08-07 Sage Therapeutics Inc Oxysteroler og fremgangsmåder til anvendelse deraf
KR102521573B1 (ko) 2016-10-18 2023-04-14 세이지 테라퓨틱스, 인크. 옥시스테롤 및 그의 사용 방법
JP7670626B2 (ja) 2019-05-31 2025-04-30 セージ セラピューティクス， インコーポレイテッド 神経刺激性ステロイド及びその組成物
US20250186408A1 (en) * 2021-05-03 2025-06-12 Katholieke Universiteit Leuven Treatment of pharmacoresistant epilepsy
CN119661621A (zh) * 2024-12-13 2025-03-21 北京华睿鼎信科技有限公司 甾类化合物及其制备方法、药物组合物及应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1430942A (en) * 1972-05-05 1976-04-07 Glaxo Lab Ltd 21-substituted 3alpha-hydroxy pregnanes
WO1994027608A1 (en) * 1993-05-24 1994-12-08 Cocensys, Inc. Methods and compositions for inducing sleep
WO1996040043A2 (en) * 1995-06-06 1996-12-19 Cocensys, Inc. Neuroactive steroids of the androstane and pregnane series

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1430942A (en) * 1972-05-05 1976-04-07 Glaxo Lab Ltd 21-substituted 3alpha-hydroxy pregnanes
WO1994027608A1 (en) * 1993-05-24 1994-12-08 Cocensys, Inc. Methods and compositions for inducing sleep
WO1996040043A2 (en) * 1995-06-06 1996-12-19 Cocensys, Inc. Neuroactive steroids of the androstane and pregnane series

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ERCOLI ET AL: "Sugli Acidi Biliari e loro Derivati. Nota IV - Un Nouvo Metodo di Demolizione Graduale. Sua Applicazione alla Degradazione dell'Acido Litocolico", FARMACO., vol. 6, 1951, SOCIETA CHIMICA ITALIANA, PAVIA., IT, pages 547, XP001025589, ISSN: 0014-827X *
PETTIT G R ET AL: "BUFADIENOLIDES. 13. CONVERSION OF 3BETA-HYDROXY-17-OXOANDROST-5-ENE TO 3BETA-ACETOXY-5BETA,14ALPHA-BUFA-20,22-DIENOLIDE", JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, US, vol. 36, no. 21, 22 October 1971 (1971-10-22), pages 3207 - 3211, XP002029626, ISSN: 0022-3263 *

Also Published As

Publication number Publication date
WO2002053577A2 (en) 2002-07-11
US7064116B2 (en) 2006-06-20
AU2002217353A1 (en) 2002-07-16
WO2002053577A3 (en) 2002-10-10
US20050176976A1 (en) 2005-08-11

Similar Documents

Publication Publication Date Title
WO2002053577A3 (en) Gabaa modulating neurosteroids
SG157231A1 (en) Substituted p-diaminobenzene derivatives
MXPA05010630A (es) Compuestos de benzopirano utiles para tratar estados inflamatorios.
TNSN07021A1 (fr) Derives de quinazoline -4-yl-piperidine et cinnoline -4-yl-piperidine servant d'inhibiteurs de pde10 pour le traitement de troubles du snc
EA200600294A1 (ru) [1,8] нафтиридин-2-оны и родственные соединения для лечения шизофрении
CA2449729A1 (en) Prodrugs of gaba analogs, compositions and uses thereof
NZ544591A (en) Pyrrolodihydroisoquinolines as PDE10 inhibitors
YU63202A (sh) Derivati 2-okso-1-pirolidina, postupci za njihovo dobijanje i njihove upotrebe
MX2007013263A (es) Novedosos derivados oxadiazol y su uso medico.
IN2006KO01346A (el)
MA27769A1 (fr) Dérivées de 2-acylamino-4-phenylthiazole, leur préparation et leur application en thérapeutique
MXPA06014721A (es) Derivados de alquinilo como moduladores de los receptores de glutamato metabotropico.
BR9913701A (pt) ácidos alquil pirrolidina-3-carboxìlicos ramificados
DE60310548D1 (de) Diazabicyclische biarylderivate
ATE289310T1 (de) Heteroaryl-diazabicycloalkanderivaten als cns- modulatoren
DE60309740D1 (de) 1,4-dizabicyclo(3,2,2)nonane derivative, verfahren zur ihre herstellung und therapeutical verwendung
DK1406900T3 (da) Hidtil ukendte forbindelser, fremstilling og anvendelse deraf
DK2212282T3 (da) Substituerede N-phenylbipyrrolidincarboxamider og terapeutisk anvendelse deraf
WO2002042256A3 (en) N-alkylated gaba compounds, processes for their preparation and their use as medicaments
GB0428232D0 (en) Compounds
WO2004047727A3 (en) Compositions and methods for diagnosing and treating mood disorders
MY129575A (en) Methods, kits and compositions for using pyrrole derivatives againts anxiety
IL117295A (en) 4-Aminotetrahydro-benzisoxazole or-isothiazole compounds and pharmaceutical compositions comprising them
BR0011039A (pt) Análogos de gaba substituìdos com 3-heteroarilalquila
MX2007012624A (es) Derivados de benzimidazol y su uso para la modulacion del complejo del receptor gaba-a.